Jeffrey Zerillo Sells 719 Shares of Prestige Consumer Healthcare (NYSE:PBH) Stock

Jeffrey Zerillo, VP of Prestige Consumer Healthcare, sold 719 shares at $60 each, totaling $43,140. This sale reduced his ownership by 1.67%, leaving him with 42,329 shares valued at $2,539,740. The transaction was disclosed in an SEC filing. Prestige Consumer Healthcare's stock has been trading down, with recent earnings beating estimates. Institutional investors have been adjusting their positions, and analysts have issued mixed ratings on the stock.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) VP Jeffrey Zerillo sold 719 shares of Prestige Consumer Healthcare stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the transaction, the vice president directly owned 42,329 shares of the company's stock, valued at $2,539,740. This represents a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jeffrey Zerillo also recently made the following trade(s):

On Monday, December 1st, Jeffrey Zerillo sold 281 shares of Prestige Consumer Healthcare stock. The stock was sold at an average price of $60.00, for a total transaction of $16,860.00.

Prestige Consumer Healthcare Trading Down 0.2%

PBH opened at $59.80 on Wednesday. Prestige Consumer Healthcare Inc. has a 1-year low of $57.25 and a 1-year high of $90.04. The stock has a market capitalization of $2.88 billion, a PE ratio of 14.04, a PEG ratio of 1.93 and a beta of 0.39. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $61.16 and a two-hundred day moving average price of $70.21.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The business had revenue of $274.11 million for the quarter, compared to analysts' expectations of $257.14 million. During the same period in the prior year, the firm earned $1.09 earnings per share. Prestige Consumer Healthcare's revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors and hedge funds have recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $41,848,000. Kayne Anderson Rudnick Investment Management LLC grew its stake in Prestige Consumer Healthcare by 45.3% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company's stock valued at $135,903,000 after acquiring an additional 493,199 shares during the period. Invesco Ltd. increased its holdings in shares of Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after acquiring an additional 261,537 shares in the last quarter. Tributary Capital Management LLC raised its position in shares of Prestige Consumer Healthcare by 157.3% during the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company's stock worth $23,675,000 after purchasing an additional 231,969 shares during the period. Finally, Squarepoint Ops LLC lifted its holdings in shares of Prestige Consumer Healthcare by 316.1% during the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company's stock valued at $18,836,000 after purchasing an additional 229,311 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PBH shares. Canaccord Genuity Group cut their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a "buy" rating on the stock in a research note on Friday, November 7th. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a "hold" rating on the stock in a research report on Monday, October 27th. Oppenheimer lowered their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an "outperform" rating for the company in a research report on Tuesday, October 21st. Zacks Research upgraded shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of "Moderate Buy" and an average target price of $85.33.

Check Out Our Latest Research Report on PBH

Prestige Consumer Healthcare Company Profile

(Get Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.